Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_4
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
unknown1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (50.0%)
Phase 41 (50.0%)

Trials by Status

terminated133%
unknown133%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
completed

ZETA : Prospective Observational Study

NCT03730558
unknownphase_4

Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer

NCT04810585
terminatedphase_2

Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer

NCT02045030

Clinical Trials (3)

Showing 3 of 3 trials
NCT03730558

ZETA : Prospective Observational Study

Completed
NCT04810585Phase 4

Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer

Unknown
NCT02045030Phase 2

Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3